RVMD Revolution Medicines Inc

$36.45

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/18/2025

About Revolution Medicines Inc

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Website: https://www.revmed.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1628171
Address
700 SAGINAW DR, REDWOOD CITY, CA, US
Valuation
Market Cap
$6.83B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
3.02
Performance
EPS
$-3.58
Dividend Yield
—
Profit Margin
0.00%
ROE
-29.30%
Technicals
50D MA
$38.30
200D MA
$44.29
52W High
$62.40
52W Low
$29.17
Fundamentals
Shares Outstanding
186M
Target Price
$72.33
Beta
1.37

RVMD EPS Estimates vs Actual

● Estimated
● Actual

RVMD News & Sentiment

Aug 15, 2025 • Benzinga SOMEWHAT-BULLISH
This Parker-Hannifin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Exodus Movement ( AMEX:EXOD ) , ICU Medical ( NASDAQ:ICUI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wells Fargo initiated coverage on Revolution Medicines, Inc.
Aug 12, 2025 • Zacks Commentary SOMEWHAT-BULLISH
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
Aug 11, 2025 • Benzinga NEUTRAL
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - KalVista Pharmaceuticals ( NASDAQ:KALV ) , Metagenomi ( NASDAQ:MGX )
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Metagenomi, Inc. MGX ( the "Company" ) , a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to ...
Aug 07, 2025 • Motley Fool SOMEWHAT-BULLISH
Royalty Pharma ( RPRX ) Q2 Receipts Up 20%
Royalty Pharma Plc ( NASDAQ:RPRX ) , a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts-its closest revenue proxy-rose 11% to $672 million but landed just under the $672.99 million analyst ...
Aug 06, 2025 • Motley Fool NEUTRAL
Tango ( TNGX ) Q2 Revenue Drops 52%
Tango Therapeutics ( NASDAQ:TNGX ) , a biotechnology firm advancing targeted oncology therapies, posted its second quarter results on August 5, 2025. The highlight of the release was a steep decline in GAAP revenue, well below consensus, along with a larger net loss compared to analyst ...
Aug 05, 2025 • GlobeNewswire NEUTRAL
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
- First patient dosed in combination trial of TNG462 and Revolution Medicines RAS ( ON ) inhibitors ...
Sentiment Snapshot

Average Sentiment Score:

0.054
50 articles with scored sentiment

Overall Sentiment:

Neutral

RVMD Reported Earnings

Feb 24, 2025
Dec 31, 2024 (Post market)
-0.16 Surprise
  • Reported EPS: $-1.12
  • Estimate: $-0.96
  • Whisper: —
  • Surprise %: -16.1%
Nov 06, 2024
Sep 30, 2024 (Post market)
-0.05 Surprise
  • Reported EPS: $-0.94
  • Estimate: $-0.89
  • Whisper: —
  • Surprise %: -5.6%
Aug 07, 2024
Jun 30, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $-0.81
  • Estimate: $-0.77
  • Whisper: —
  • Surprise %: -5.2%
May 08, 2024
Mar 31, 2024 (Post market)
0.05 Surprise
  • Reported EPS: $-0.70
  • Estimate: $-0.75
  • Whisper: —
  • Surprise %: 6.7%
Feb 26, 2024
Dec 31, 2023 (Post market)
-0.26 Surprise
  • Reported EPS: $-1.14
  • Estimate: $-0.88
  • Whisper: —
  • Surprise %: -29.6%
Nov 06, 2023
Sep 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $-0.99
  • Estimate: $-1.01
  • Whisper: —
  • Surprise %: 2.0%
Aug 08, 2023
Jun 30, 2023 (Post market)
-0.1 Surprise
  • Reported EPS: $-0.92
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: -12.2%
May 08, 2023
Mar 31, 2023 (Post market)
0.09 Surprise
  • Reported EPS: $-0.72
  • Estimate: $-0.81
  • Whisper: —
  • Surprise %: 11.1%
Feb 27, 2023
Dec 31, 2022 (Post market)
0.19 Surprise
  • Reported EPS: $-0.63
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: 23.2%

Financials